Vicente Carañana

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

François‐Clément Bidard, Dieter Peeters, Tanja Fehm et al. · The Lancet Oncology · 2014 · 838 citations

Medicine, Cancer Biology, Oncology +17

Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain

Rámón Colomer, Antonio Llombart‐Cussac, Aňa Lluch et al. · Annals of Oncology · 2004 · 90 citations

Medicine, Oncology, Pharmacology +17

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.

Antonio Llombart‐Cussac, Catherine Harper‐Wynne, Antonia Perelló et al. · Journal of Clinical Oncology · 2023 · 72 citations

Medicine, Oncology, Pharmacology +17

Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

Antonio Llombart‐Cussac, Ángel Guerrero, António Galán de Mera et al. · Clinical & Translational Oncology · 2012 · 71 citations

Medicine, Oncology, Pharmacology +13

Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

José Manuel Pérez-García, Antonio Llombart‐Cussac, María Gión et al. · European Journal of Cancer · 2021 · 41 citations

Medicine, Oncology, Pharmacology +16